GALNT14: An emerging marker capable of predicting therapeutic outcomes in multiple cancers

Wey Ran Lin, Chau Ting Yeh*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


Members of the polypeptide N-acetylgalactosaminyltransferase (GALNT) family function as the initiating enzymes that catalyze mucin-type O-glycosylation of proteins, and their dysregulated expression can alter cancer cell behaviors such as de novo occurrence, proliferation, migration, metastasis, and drug resistance. Recent studies have demonstrated that one of the family’s members, GALNT14, is aberrantly expressed in multiple cancers and involved in a variety of biological functions. Moreover, the single nucleotide polymorphisms (SNPs) of GALNT14-rs9679162 have been shown to predict therapeutic outcomes in patients with hepatocellular carcinoma as well as several other different types of gastrointestinal cancer. This review summarizes the structural features of GANLT14, its functional roles, and the predictive values of GALNT14 genotypes and enzyme levels in multiple cancers receiving distinct anticancer therapies.

Original languageEnglish
Article number1491
JournalInternational Journal of Molecular Sciences
Issue number4
StatePublished - 02 02 2020

Bibliographical note

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.


  • Biomarker
  • Cancer
  • Polypeptide N-acetylgalactosaminyltransferase
  • Single nucleotide polymorphism


Dive into the research topics of 'GALNT14: An emerging marker capable of predicting therapeutic outcomes in multiple cancers'. Together they form a unique fingerprint.

Cite this